Abstract Body

Background:

Antiretroviral therapy efficiently supresses HIV-1 replication but does not eradicate the virus. New approaches aimed at eliminating infected cells represent an appealing avenue to achieve this goal. Non-neutralizing antibodies (nnAbs) naturally present in the plasma of people living with HIV-1 (PLWH) have the potential to eliminate HIV-1-infected cells via antibody-dependent cellular cytotoxicity (ADCC). However, these nnAbs largely recognize epitopes only accessible upon interaction of the envelope glycoproteins (Env) with CD4. HIV-1 limits surface Env-CD4 interaction by downregulating CD4, thus protecting infected cells from CD4-induced (CD4i) nnAb-mediated ADCC responses. CD4-mimetic compounds (CD4mcs) can ‘open-up’ Env and sensitize HIV-1-infected cells to ADCC mediated by HIV+ plasma. We have shown that two families of CD4i nnAbs contribute to eliminate infected cells in the presence of CD4mc: the anti-cluster A and the anti-coreceptor binding site (CoRBS) Abs. Of note, while indane CD4mcs significantly enhance the recognition of infected cells by anti-CoRBS Abs, these nnAbs mediate ADCC poorly. The combination of anti-CoRBS Abs together with CD4mc and anti-Cluster A is required to mediate ADCC. This combination reduces the size of the HIV-1 reservoir and delays viral rebound after ART interruption in humanized mice. The development of new indoline CD4mc with improved neutralization potency and breath enabled us to revisit the capacity of anti-CoRBS Abs to mediate ADCC.

Methods:

The capacity of anti-CoRBS Abs to mediate ADCC against HIV-1-infected cells in the presence of indane and indoline CD4mcs was assessed in vitro, while their capacity to delay viral rebound in vivo was evaluated in infected humanized mice.

Results:

Contrary to indane CD4mcs, we found that the lead indoline CD4mc, CJF-III-288, sensitizes HIV-1-infected cells to ADCC mediated by anti-CoRBS Abs. This was observed with multiple HIV-1 primary strains and using various anti-CoRBS Abs. Accordingly, treatment of humanized mice with CJF-III-288 and an CoRBS Ab alone was sufficient to delay viral rebound after ART interruption, and notably, for much longer when administered prior to ART initiation. These results suggest that the indoline CD4mc ‘open’ the Env trimer in such a way that favors Fc gamma receptor engagement on effector cells.

Conclusions:

More potent indoline CD4mc have the ability to sensitize HIV-1-infected cells to CoRBS Abs-mediated ADCC responses, thereby improving their therapeutic potential.